Dual-specific CARs targeting CD19/CD79b, CD19/CD38, CD19/CD123, and CD19/CD37 have shown promising anti-tumor activity in vitro and in vivo [146,147,148,149,150,151]. Here, CD19 is linked to neoplasm.